Merck KGaA Raises Guidance as Q3 Sales Climb 6%

Merck KGaA raised its full-year sales guidance to a range of €21.5 to €21.9 billion, signaling confidence following a surprisingly strong third quarter. The revised forecast, up from a previous estimate of €21.0 to €21.8 billion, reflects robust performance across key divisions, particularly its life science and pharmaceutical businesses.

The company benefited from continued strong demand within its life science division, specifically for products and solutions related to pharmaceutical production. Growth in medications for rare diseases within the pharmaceutical segment, as well as materials for artificial intelligence semiconductors in its electronics business, further contributed to the positive results. Total sales for the quarter increased by nearly 6% year-over-year, reaching €5.63 billion.

While operating profit saw a slight increase to just over €1.68 billion, earnings per share remained stable at €2.32. This stability occurred despite analysts anticipating a decline in both earnings and revenue, underscoring the strength of Merck KGaA’s recent performance. The adjusted EBITDA is now projected to reach between €6.2 and €6.4 billion, an increase from the previous projection of €5.9 to €6.3 billion.

The upward revision in guidance demonstrates Merck KGaA’s ability to capitalize on strong demand in its core markets, particularly within the high-growth areas of drug production and AI-related technologies. The company's resilience is evident in its ability to exceed analyst expectations and maintain a stable earnings per share despite a challenging macroeconomic environment.